Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.84M | 14.52M | 11.65M | 9.69M | 63.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.84M | 14.52M | 11.65M | 9.69M | 63.75M |
| Cost of Revenue | 31.70M | 36.55M | 36.64M | 39.85M | 38.33M |
| Gross Profit | -21.86M | -22.03M | -25.00M | -30.16M | 25.42M |
| SG&A Expenses | 7.83M | 7.58M | 8.66M | 8.74M | 10.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.53M | 44.14M | 45.30M | 48.59M | 48.67M |
| Operating Income | -29.69M | -29.61M | -33.66M | -38.90M | 15.08M |
| Income Before Tax | -38.53M | -38.50M | -46.84M | -56.86M | -11.52M |
| Income Tax Expenses | 1.00K | -15.00K | -82.00K | -- | -18.00K |
| Earnings from Continuing Operations | -38.53M | -38.48M | -46.76M | -56.86M | -11.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.53M | -38.48M | -46.76M | -56.86M | -11.50M |
| EBIT | -29.69M | -29.61M | -33.66M | -38.90M | 15.08M |
| EBITDA | -28.43M | -28.34M | -32.03M | -37.00M | 16.98M |
| EPS Basic | -2.33 | -2.94 | -5.35 | -6.70 | -1.35 |
| Normalized Basic EPS | -1.45 | -1.84 | -3.04 | -3.48 | 0.51 |
| EPS Diluted | -2.33 | -2.94 | -5.35 | -6.70 | -1.35 |
| Normalized Diluted EPS | -1.45 | -1.84 | -3.04 | -3.48 | 0.51 |
| Average Basic Shares Outstanding | 16.57M | 13.08M | 8.73M | 8.49M | 8.51M |
| Average Diluted Shares Outstanding | 16.57M | 13.08M | 8.73M | 8.49M | 8.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |